The Wall Street Transcript
The Wall Street Transcript - In-Depth Interviews for Investors
Healthcare >> CEO Interviews >> October 23, 2015

Interview with the President and CEO: Soligenix, Inc. (OTCBB:SNGX)

Schaber, Christopher J.
Christopher J. Schaber, Ph.D., is President and Chief Executive Officer of Soligenix, Inc. He has over 25 years of experience in the pharmaceutical and biotechnology industry. Dr. Schaber has been President and Chief Executive Officer and a director of Soligenix (OTCBB:SNGX) since August 2006. He was appointed Chairman of the board on October 8, 2009. He also serves on the board of directors of the Biotechnology Council of New Jersey — BioNJ — since January 2009 and the Alliance for Biosecurity since October 2014, and has been a member of the corporate councils of both the National Organization for Rare Diseases — NORD — and the American Society for Blood and Marrow Transplantation — ASBMT — since October 2009 and July 2009, respectively. Prior to joining Soligenix, Dr. Schaber served from 1998 to 2006 as Executive Vice President and Chief Operating Officer of Discovery Laboratories, Inc., where he was responsible for overall pipeline development and key areas of commercial operations, including regulatory affairs, quality control and assurance, manufacturing and distribution, preclinical and clinical research, and medical affairs, as well as coordination of commercial launch preparation activities. From 1996 to 1998, Dr. Schaber was a Co-Founder of Acute Therapeutics, Inc., and served as its Vice President of Regulatory Compliance and Drug Development. From 1994 to 1996, Dr. Schaber was employed by Ohmeda PPD, Inc., as Worldwide Director of Regulatory Affairs and Operations. From 1989 to 1994, Dr. Schaber held a variety of regulatory, development and operations positions with The Liposome Company, Inc., and Elkins-Sinn Inc., a division of Wyeth-Ayerst Laboratories. Dr. Schaber received his B.A. degree from Western Maryland College, his M.S. degree in pharmaceutics from Temple University School of Pharmacy and his Ph.D. degree in pharmaceutical sciences from the Union Graduate School. Profile
TWST: Can you describe your company and its purpose?

Dr. Schaber: Our company’s tagline concisely describes its purpose, and that is: rising to the challenges of rare disease

Top Company Interviews

Microsoft Corporation
Intel Corporation
Pfizer, Inc.
General Electric Company
Walmart Inc.
International Business Machines Corporation
Citigroup Inc.
Exxon Mobil Corporation
Bank of America Corporation
Dell Inc.
Verizon Communications Inc.
Alphabet Inc

Register for a Free Account to gain greater access to The Wall Street Transcript right now

CEO INTERVIEWS
Interview with the CEO: BetterLife Pharma Inc. (OTCMKTS:BETRF)
Interview with the CEO: Cansortium Inc. (OTCMKTS:CNTMF)
Interview with the Co-CEO and the CAO: Planet 13 Holdings Inc. (OTCMKTS:PLNH)
SECTOR ROUNDTABLES
Natural Gas Weighs Heavy On E&P Near-Term Prospects
Roundtable Forum:optimism Despite Uncertainty In For-profit Education
Roundtable Forum:a Shift In Focus To Natural Gas From Oil
MONEY MANAGER INTERVIEWS
Profitability Strategy Pays Off for Bank IT Company Q2 Holdings
Three Mid-Cap Names Using Their Balance Sheets to Create Value
Look Beyond Traditional Emerging Markets for More Diversification, Less Risk
ANALYST INTERVIEWS
Five Companies Dominate in Psychedelics-Based Drug Development
Cidara’s Long-Acting Antiviral Drug Could Be a Game Changer
Spotting Potential in the High-Risk, High Reward Neuroscience Space
Since 1963
© The Wall Street Transcript 2016, 2024
Terms and Conditions
Privacy Policy